CADL — Candel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1841387 ·
Last close
$5.40
Market Cap
$423.61M
52W High
$14.00
52W Low
$4.35
ADV30
1,370,954
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -22,958,000 | -21,873,000 | 211,110,000 | 203,116,000 | 79,519,000 |
| Jun 2026 | 0 | — | -26,724,000 | -38,905,000 | 208,149,000 | 201,565,000 | 82,019,000 |
| Mar 2026 | 0 | — | -16,262,000 | -8,861,000 | 201,920,000 | 194,834,000 | 63,891,000 |
| Dec 2025 | 0 | — | -15,663,000 | -29,496,000 | 125,195,000 | 119,731,000 | 73,273,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,023,000
Investing CF
$-1,270,000
Financing CF
$158,321,000
CapEx
$-1,297,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-278,153,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-83,815,000
Pretax Income TTM
$-88,531,000
Interest Exp TTM
$4,716,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,177,000 | -38,182,000 | 125,195,000 | 73,273,000 | 51,922,000 | -38,311,000 |
| Dec 2024 | 0 | -33,371,000 | -55,177,000 | 106,866,000 | 40,539,000 | 66,327,000 | -27,023,000 |
| Dec 2023 | 0 | -38,391,000 | -37,939,000 | 41,201,000 | 28,456,000 | 12,745,000 | -34,244,000 |
| Dec 2022 | 125,000 | -34,674,000 | -18,794,000 | 77,691,000 | 29,977,000 | 47,714,000 | -31,419,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-88,531,000
OpCashFlow TTM
—
Assets (Latest)
$208,149,000
Forward EPS
$-1.47
Max Pain — expiry 2027-01-15
max pain strike: $7.00 · spot: $5.32 · call oi: 5,393 · put oi: 798
Expected Move to 2027-01-15:
±$2.30
(43.23%) —
implied range
$3.02 –
$7.62
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRLA | IRulya Therapeutics Inc. | $416.85M | $38.45 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $448.81M | $8.32 | — |
| TECX | Tectonic Therapeutic, Inc. | $392.55M | $20.08 | — |
| ALEC | Alector, Inc. | $381.13M | $2.56 | — |
| RGNX | REGENXBIO Inc. | $478.73M | $7.24 | — |
News headlines (Yahoo Finance, 1h cache)
PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month
2026-11-16 16:42 · Yahoo
Candel Therapeutics (CADL) Stock Fair Value Moves Lower After Analysts Cut Targets
2026-11-15 09:09 · Yahoo
CADL Stock Heads For Worst Ever Session — Stifel Expects Prostate Cancer Drug Launch To Be Pushed to Mid-2028
2026-11-13 14:41 · Yahoo
Candel Therapeutics stock plummets 35% on prostate cancer BLA delay
2026-11-13 14:17 · Yahoo
CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027
2026-11-12 23:13 · Yahoo
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-12 21:05 · Yahoo
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
2026-11-06 14:00 · Yahoo
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:05 · Yahoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 21:05 · Yahoo
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
2026-10-29 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.